구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Pexa Vec (Pexastimogene Devacirepvec, Pexastimogene Devacirepvec (Pexa Vec)) SillaJen, Inc.·Hepatocellular Carcinoma (HCC) 18 trials |
|---|---|
Overview Program | Pexastimogene Devacirepvec (Pexa Vec) |
Overview Company | SillaJen, Inc. |
Overview Modality | CGT |
Overview Target | Hepatocellular Carcinoma (HCC) |
Overview Indication | Hepatocellular Carcinoma (HCC) |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.. Oncolytic immunotherapy represents a unique therapeutic platform for the treatment of cancer. Here, we evaluated the safety and efficacy of the combination of pexastimogene devacirepvec (PexaVec) plus durvalumab (anti-programmed death ligand 1) with and without tremelimumab (an… |
Clinical Safety signal | Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.. Oncolytic immunotherapy represents a unique therapeutic platform for the treatment of cancer. Here, we evaluated the safety and efficacy of the combination of pexastimogene devacirepvec (PexaVec) plus durvalumab (anti-programmed death ligand 1) with and without tremelimumab (an… |
Clinical Selected reported efficacy | ORR 33.3% |
Clinical Reported ORR | 33.3% |
Clinical Result source | ClinicalTrials.gov NCT03071094 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT03071094 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Pexa Vec (Pexastimogene Devacirepvec, Pexastimogene Devacirepvec (Pexa Vec)) SillaJen, Inc.·Hepatocellular Carcinoma (HCC) 18 trials |
|---|---|
Overview Program | Pexastimogene Devacirepvec (Pexa Vec) |
Overview Company | SillaJen, Inc. |
Overview Modality | CGT |
Overview Target | Hepatocellular Carcinoma (HCC) |
Overview Indication | Hepatocellular Carcinoma (HCC) |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.. Oncolytic immunotherapy represents a unique therapeutic platform for the treatment of cancer. Here, we evaluated the safety and efficacy of the combination of pexastimogene devacirepvec (PexaVec) plus durvalumab (anti-programmed death ligand 1) with and without tremelimumab (an… |
Clinical Safety signal | Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.. Oncolytic immunotherapy represents a unique therapeutic platform for the treatment of cancer. Here, we evaluated the safety and efficacy of the combination of pexastimogene devacirepvec (PexaVec) plus durvalumab (anti-programmed death ligand 1) with and without tremelimumab (an… |
Clinical Selected reported efficacy | ORR 33.3% |
Clinical Reported ORR | 33.3% |
Clinical Result source | ClinicalTrials.gov NCT03071094 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT03071094 |
추천 비교
추천 비교